A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Apollo Hospitals Saves 41 Yr Old Farmer Who Waited 91 Days for a Heart Transplant with Mitral Chip Implant

Apollo Hospitals, Asia’s foremost and most trusted healthcare group, today announced a successful MitraClip implant on a 41-year-old male farmer who had waited for over three months in different hospitals for a heart transplant. The patient was back on his feet within a few days after the procedure, and might not even need a heart transplant.

Ms. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Group said, “As one of the few hospitals in India accredited to perform the MitraClip procedure, being able to save the life of a patient waiting for a heart transplant gives us the ability to offer hope to many others. Research has shown that using MitraClip as a bridge to heart transplantation is safe and may lead to functional improvements that permit patients to be removed from the transplant list. We are proud to have demonstrated this at Apollo Hospitals through the case of a 41-year-old male patient who was waiting for a heart transplant for over three months. The success of this case has renewed our commitment to taking this cutting edge and revolutionary medical innovation to the people who need it the most.”

Dr. Sai Satish, Senior Interventional Cardiologist, Apollo Hospitals said, “The MitraClip is a globally accepted procedure for patients with heart failure. For three years now we have been performing this procedure on patients and we have seen incredible results in the quality of life they are able to return to. Our experience in this domain has enabled us to achieve many milestones including back-to-back MitraClip implants in four very sick patients in just one day. Today, we are at pole position; 70% of all MitraClips in India to date have been performed at Apollo Hospitals and we are only looking at bigger milestones in the journey ahead.”

India’s first two scientific papers on MitraClip have both been published from Apollo Hopsitals. Dr. Sai Satish is involved in the authorship of the APAC guidelines for MitraClip implants. Asia’s first MitraClip training programme that included theory and four cases over two days was conducted at Apollo Hospitals, cementing its position as a Centre of Excellence in Interventional Cardiology.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy